Neil Lerner Biography and Net Worth

Senior Vice President, Chief Accounting Officer of Compass Therapeutics

Neil Lerner joined Compass in 2020 as a finance leader with over 20 years of accounting, finance and business experience, including SEC reporting, system implementations, budgeting and forecasting, Sarbanes Oxley (SOX), and cost accounting.

Prior to joining Compass, Neil led the accounting and finance function of Psychemedics Corporation, a publicly traded diagnostic company. Prior to Psychemedics, Neil assumed several financial leadership roles with Johnson & Johnson, including partnering with the R&D team and new business development organization, leading an enterprise resource planning implementation, plant controller, and as an internal auditor. Additional positions Neil held include Director of Operational Accounting at Beacon Roofing Supply, Inc., and a Controller with Mastec, Inc.

Neil is a CPA and has a master’s degree in international management from the University of Denver.

What is Neil Lerner's net worth?: The estimated net worth of Neil Lerner is at least $454 thousand as of September 24th, 2026. Mr. Lerner owns 400,000 shares of Compass Therapeutics stock worth more than $454,000 as of September 25th. This net worth evaluation does not reflect any other assets that Mr. Lerner may own. Learn More about Neil Lerner's net worth.
How do I contact Neil Lerner?: The corporate mailing address for Mr. Lerner and other Compass Therapeutics executives is 80 Guest Street, Boston, MA, 02135. Compass Therapeutics can also be reached via phone at 617-500-8099 and via email at [email protected]. Learn More on Neil Lerner's contact information.
Has Neil Lerner been buying or selling shares of Compass Therapeutics?: During the last quarter, Neil Lerner has bought $2,850.00 in shares of Compass Therapeutics stock. Most recently, on Thursday, September 24th, Neil Lerner bought 2,500 shares of Compass Therapeutics stock. The stock was acquired at an average cost of $1.14 per share, with a total value of $2,850.00. Following the completion of the transaction, the chief accounting officer now directly owns 400,000 shares of the company's stock, valued at $456,000. Learn More on Neil Lerner's trading history.
Who are Compass Therapeutics' active insiders?: Compass Therapeutics' insider roster includes Jonathan Anderman (Insider), Carl Gordon (Director), Neil Lerner (Senior Vice President, Chief Accounting Officer), and Thomas Schuetz (CEO). Learn More on Compass Therapeutics' active insiders.
Are insiders buying or selling shares of Compass Therapeutics?: During the last twelve months, Compass Therapeutics insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $2,850.00. The most recent insider tranaction occured on September, 24th when CAO Neil Lerner bought 2,500 shares worth more than $2,850.00. Insiders at Compass Therapeutics own 18.7% of the company. Learn More about insider trades at Compass Therapeutics.
Information on this page was last updated on 9/24/2026.

Neil Lerner Insider Trading History at Compass Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/24/2026	Buy	2,500	$1.14	$2,850.00	400,000

Neil Lerner Buying and Selling Activity at Compass Therapeutics

Compass Therapeutics Company Overview

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $1.15

$1.15

$1.20

50 Day Range

MA: $2.10

$1.14

$2.53

2 Week Range

Now: $1.15

$1.10

$6.88

Volume

590,601 shs

Average Volume

4,553,136 shs

Market Capitalization

$206.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95